Giant Biogene (2367) Announces Share Repurchase Plan Under General Mandate

Bulletin Express12-02

Giant Biogene Holding Co., Ltd. (2367) has announced a proposal to exercise its general mandate for the repurchase of up to 103,590,400 shares, equivalent to 10% of its issued shares (excluding treasury shares). The mandate was granted during the company’s Annual General Meeting on 13 June 2025 and will remain valid until the earlier of the next AGM, the deadline for holding the next AGM as required by relevant regulations, or a revocation by shareholders.

According to the announcement dated 2 December 2025, the repurchase is to be financed from the company’s own funds, with no material adverse impact anticipated on the Group’s working capital. The repurchased shares will be cancelled and/or held as treasury shares in line with all applicable laws and regulations, including the Listing Rules and the Codes on Takeovers and Mergers. The Board emphasizes that market conditions will dictate the implementation and timing of any repurchases, which are not guaranteed.

The company’s leadership views its current share price as undervaluing its long-term prospects and believes the repurchase will help enhance financial indicators, including earnings per share. They see the plan as beneficial to overall capital management and optimization of the company’s structure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103748425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103748425","market":"us","top_or_hot":-1,"title":"Giant Biogene (2367) Announces Share Repurchase Plan Under General Mandate","media":"Bulletin Express","content":"<p>Giant Biogene Holding Co., Ltd. (2367) has announced a proposal to exercise its general mandate for the repurchase of up to 103,590,400 shares, equivalent to 10% of its issued shares (excluding treasury shares). The mandate was granted during the company’s Annual General Meeting on 13 June 2025 and will remain valid until the earlier of the next AGM, the deadline for holding the next AGM as required by relevant regulations, or a revocation by shareholders.</p>\n<p>According to the announcement dated 2 December 2025, the repurchase is to be financed from the company’s own funds, with no material adverse impact anticipated on the Group’s working capital. The repurchased shares will be cancelled and/or held as treasury shares in line with all applicable laws and regulations, including the Listing Rules and the Codes on Takeovers and Mergers. The Board emphasizes that market conditions will dictate the implementation and timing of any repurchases, which are not guaranteed.</p>\n<p>The company’s leadership views its current share price as undervaluing its long-term prospects and believes the repurchase will help enhance financial indicators, including earnings per share. They see the plan as beneficial to overall capital management and optimization of the company’s structure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene (2367) Announces Share Repurchase Plan Under General Mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene (2367) Announces Share Repurchase Plan Under General Mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-02 12:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Giant Biogene Holding Co., Ltd. (2367) has announced a proposal to exercise its general mandate for the repurchase of up to 103,590,400 shares, equivalent to 10% of its issued shares (excluding treasury shares). The mandate was granted during the company’s Annual General Meeting on 13 June 2025 and will remain valid until the earlier of the next AGM, the deadline for holding the next AGM as required by relevant regulations, or a revocation by shareholders.</p>\n<p>According to the announcement dated 2 December 2025, the repurchase is to be financed from the company’s own funds, with no material adverse impact anticipated on the Group’s working capital. The repurchased shares will be cancelled and/or held as treasury shares in line with all applicable laws and regulations, including the Listing Rules and the Codes on Takeovers and Mergers. The Board emphasizes that market conditions will dictate the implementation and timing of any repurchases, which are not guaranteed.</p>\n<p>The company’s leadership views its current share price as undervaluing its long-term prospects and believes the repurchase will help enhance financial indicators, including earnings per share. They see the plan as beneficial to overall capital management and optimization of the company’s structure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1103748425","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103748425","pubTimestamp":1764650696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Giant Biogene Holding Co., Ltd. (2367) has announced a proposal to exercise its general mandate for the repurchase of up to 103,590,400 shares, equivalent to 10% of its issued shares (excluding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物"},"translate_title":"巨人生物(2367)公布根据一般授权购回股份计划","themeId":"93fb2e47c9fd33d3ba859dde5032b51d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"Giant Biogene Holding Co., Ltd. (2367) has announced a proposal to exercise its general mandate for the repurchase of up to 103,590,400 shares, equivalent to 10% of its issued shares (excluding treasury shares). The mandate was granted during the company’s Annual General Meeting on 13 June 2025 and will remain valid until the earlier of the next AGM, the deadline for holding the next AGM as required by relevant regulations, or a revocation by shareholders.\nAccording to the announcement dated 2 December 2025, the repurchase is to be financed from the company’s own funds, with no material adverse impact anticipated on the Group’s working capital. The repurchased shares will be cancelled and/or held as treasury shares in line with all applicable laws and regulations, including the Listing Rules and the Codes on Takeovers and Mergers. The Board emphasizes that market conditions will dictate the implementation and timing of any repurchases, which are not guaranteed.\nThe company’s leadership views its current share price as undervaluing its long-term prospects and believes the repurchase will help enhance financial indicators, including earnings per share. They see the plan as beneficial to overall capital management and optimization of the company’s structure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103748425","isCrawlerRequest":true}